AAPL 192.055 0.5313% MSFT 429.86 1.0627% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 462.96 -1.2542% TSLA 180.94 3.4238% TSM 153.09 -0.2996% LLY 803.41 2.5831% V 275.395 -1.1291% AVGO 1404.87 -0.6478% JPM 197.75 1.1095% UNH 522.3085 0.9819% NVO 134.5 1.1963% WMT 64.925 1.1608% LVMUY 166.99 -1.1016% XOM 118.24 -0.3623% LVMHF 850.0 0.5917% MA 456.5317 -0.6806%

Gamida Cell Ltd

Healthcare US GMDA

0.017USD
-0.0014(7.61%)

Last update at 2024-05-20T13:30:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.222.51
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -79.37500M -89.79300M -72.70400M -34.42100M -52.86100M
Minority interest - - - - -
Net income -154.36800M -92.41900M -76.44800M -34.35100M -52.93100M
Selling general administrative 19.40M 16.98M 12.17M 12.09M 11.60M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.44M 0.43M 2.40M 2.14M 0.27M
Ebit 74.99M -87.16700M -62.30000M -48.24500M -32.87100M
Ebitda -74.55300M -86.73600M -59.66700M -28.95300M -32.60200M
Depreciation and amortization -149.54600M 0.43M 2.63M 19.29M 0.27M
Non operating income net other - - - - -
Operating income 74.99M -87.16700M -62.30000M -48.24500M -33.64400M
Other operating expenses 74.99M 87.17M 62.30M 48.24M 33.64M
Interest expense 4.38M 2.63M 10.64M 3.33M 20.26M
Tax provision - - 0.00000M -0.07000M 0.07M
Interest income - - 0.24M 1.25M 0.88M
Net interest income -4.38200M -2.62600M -3.50800M -2.07600M -1.22800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 74.99M 2.63M 3.74M -0.07000M 0.07M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 74.99M 87.17M 62.30M 48.24M 33.64M
Cost of revenue - - - - 0.00000M
Total other income expense net -154.36800M -2.62600M -10.40400M 13.82M -17.98900M
Discontinued operations - - - - -
Net income from continuing ops -79.37500M -89.79300M -72.70400M -34.35100M -52.93100M
Net income applicable to common shares - -89.79300M -72.70400M -34.35100M -52.93100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 124.77M 148.79M 155.48M 68.78M 65.16M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.89M 2.69M 2.81M 1.31M 1.50M
Total liab 132.80M 104.85M 56.75M 33.79M 40.48M
Total stockholder equity -8.02300M 43.94M 98.74M 34.98M 24.69M
Deferred long term liab - - - - -
Other current liab 15.84M 14.46M 12.69M 8.36M 4.72M
Common stock 0.21M 0.17M 0.17M 0.09M 0.07M
Capital stock 0.21M 0.17M 0.17M 0.09M 0.07M
Retained earnings -416.83200M -337.45700M -276.26800M -203.56400M -169.21300M
Other liab - 2.40M 29.81M 18.30M 33.77M
Good will - - - - -
Other assets - 7.76M 0.79M 0.64M 0.66M
Cash 64.66M 55.89M 127.17M 41.84M 40.27M
Cash and equivalents - - - - -
Total current liabilities 24.88M 25.43M 21.55M 11.39M 6.71M
Current deferred revenue - - - - -
Net debt 39.31M 23.83M -119.26000M -35.86700M -40.27200M
Short term debt 2.65M 2.70M 2.53M 1.87M -
Short long term debt - - - - -
Short long term debt total 103.97M 79.72M 7.91M 5.97M -
Other stockholder equity 408.60M 381.23M 375.28M 238.99M 193.95M
Property plant equipment - 42.42M 24.71M 11.43M 2.31M
Total current assets 66.55M 98.61M 129.99M 56.70M 62.19M
Long term investments - - - - -
Net tangible assets - 43.94M 98.74M 34.98M 24.69M
Short term investments 0.00000M 40.03M 0.00000M 13.56M 20.42M
Net receivables - - 0.10M 0.00700M -
Long term debt 96.45M 71.42M - - -
Inventory - - - - -
Accounts payable 6.38M 8.27M 6.33M 1.16M 1.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.44100M -0.53700M -0.12000M
Additional paid in capital - - - - -
Common stock total equity - - 0.17M 0.09M 0.07M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.88M 7.76M 0.79M 0.64M 0.66M
Deferred long term asset charges - - - - -
Non current assets total 58.23M 50.17M 25.50M 12.07M 2.97M
Capital lease obligations 7.51M 8.30M 7.91M 5.97M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 34.04M -40.64500M 13.55M 3.67M -0.95600M
Change to liabilities - 1.94M 5.08M -0.82100M -0.40500M
Total cashflows from investing activities - -60.92100M 1.59M 3.67M -2.75100M
Net borrowings - 70.78M -1.98500M -1.52900M -1.52900M
Total cash from financing activities 45.14M 71.40M 132.38M 35.73M 48.09M
Change to operating activities - 0.50M 3.45M 2.81M 2.30M
Net income -79.37500M -89.79300M -72.70400M -34.35100M -52.93100M
Change in cash 8.77M -71.27800M 85.33M 1.57M 18.95M
Begin period cash flow 55.89M 127.17M 41.84M 40.27M 21.32M
End period cash flow 64.66M 55.89M 127.17M 41.84M 40.27M
Total cash from operating activities -70.42300M -81.76000M -48.62700M -37.93000M -26.42600M
Issuance of capital stock 22.30M 0.00000M 133.32M 37.14M 47.48M
Depreciation 0.44M 0.43M 2.40M 2.14M 0.27M
Other cashflows from investing activities - -5.22200M -0.15800M -0.15800M -0.15000M
Dividends paid - - - 0.13M -
Change to inventory - - - - -
Change to account receivables - - -1.62600M -0.15000M 0.94M
Sale purchase of stock - - - -0.23800M 47.48M
Other cashflows from financing activities 22.85M -60.92100M 1.05M 0.49M 0.61M
Change to netincome - 2.41M 14.77M -7.55800M 23.40M
Capital expenditures 6.35M 15.05M 11.80M 3.06M 1.65M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.64M 4.57M 6.91M 1.84M 2.83M
Stock based compensation 5.04M 4.23M 2.86M 4.87M 3.58M
Other non cash items -0.16700M -1.19600M 4.79M 1.76M 1.18M
Free cash flow -76.77700M -96.81400M -60.43100M -40.98500M -28.07100M

Fundamentals

  • Previous Close 0.02
  • Market Cap38.98M
  • Volume388562
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-75.91000M
  • Revenue TTM0.67M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.82

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GMDA
Gamida Cell Ltd
-0.0014 7.61% 0.02 - - 57.92 100.69 93.99 -0.8333
NVO
Novo Nordisk A/S
1.59 1.20% 134.50 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-2.308 1.73% 130.82 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.47 1.45% 439.40 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
0.29 0.32% 93.03 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Gamida Cell Ltd

5 Nahum Heftsadie Street, Jerusalem, Israel, 91340

Key Executives

Name Title Year Born
Mr. Shai Lankry CPA, M.B.A. Chief Financial Officer 1976
Ms. Michele Ilene Korfin M.B.A., R.Ph. Chief Operating & Chief Commercial Officer 1972
Dr. Ronit Simantov M.D. Chief Medical & Chief Scientific Officer 1965
Ms. Abigail L. Jenkins Pres, CEO & Director 1976
Mr. Joshua F. Patterson Gen. Counsel & Chief Compliance Officer 1976
Mr. Paul Nee VP of Marketing NA
Mr. Naftali Brikashvili CPA Sr. VP Fin. & Operations NA
Dr. Tracey Lodie Ph.D. Scientific Advisor & Consultant 1970
Mr. Vladimir Melnikov Sr. VP of Global Operations & Manufacturing NA
Heather DiVecchia Chief of Staff NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).